LUCD logo

LUCD
Lucid Diagnostics Inc

1,877
Mkt Cap
$209.16M
Volume
772,353.00
52W High
$1.63
52W Low
$0.90
PE Ratio
-2.20
LUCD Fundamentals
Price
$1.03
Prev Close
$1.05
Open
$1.05
50D MA
$1.12
Beta
0.73
Avg. Volume
857,068.84
EPS (Annual)
-$0.6922
P/B
-27.69
Rev/Employee
$57,390.24
$156.51
Loading...
Loading...
News
all
press releases
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results PR Newswire NEW YORK, May 15, 2026...
PR Newswire
News Placeholder
More News
News Placeholder
Lucid Diagnostics Q1 Earnings Call Highlights
Lucid Diagnostics Q1 Earnings Call Highlights...
Yahoo! Finance: News
News Placeholder
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Misses Revenue Estimates
Lucid Diagnostics (LUCD) delivered earnings and revenue surprises of -40.00% and -10.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results PR Newswire NEW...
PR Newswire
News Placeholder
Hyperfine, Inc. (HYPR) Reports Q1 Loss, Beats Revenue Estimates
Hyperfine (HYPR) delivered earnings and revenue surprises of 0.00% and +14.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Lucid Diagnostics Inc. (LUCD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Lucid Diagnostics (LUCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
News Placeholder
10x Genomics (TXG) Reports Q1 Loss, Beats Revenue Estimates
10x Genomics (TXG) delivered earnings and revenue surprises of +65.52% and +3.57%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates
LivaNova (LIVN) delivered earnings and revenue surprises of +15.29% and +3.60%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026 PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026 PR Newswire...
PR Newswire
News Placeholder
Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026 Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on...
PR Newswire
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available